Adam Kinnaird, MD PhD FRCSC


Surgery / Oncology

Urologic Surgeon

I am a currently completing a one-of-a-kind fellowship in Imaging, Targeted Biopsy and Focal Therapy for Prostate Cancer at UCLA. This means that every day, at each patient encounter (whether in the clinic, during prostate biopsy or in the operating room), my decision-making process is based on accurately identifying the prostate tumor using the best imaging modality available.

I believe that my training situates me in excellent position to lead and participate in APCaRI translational research projects. During my Urology residency training I was given the opportunity to extend my education by three years to complete a PhD in Experimental Medicine within the Royal College of Physicians and Surgeons of Canada’s Clinician Investigator Program. I was fortunate to receive Canada’s top international scholarship for PhD students, the Vanier Canada Graduate Scholarship. As a Vanier Scholar I studied cancer metabolism and used novel devices to perform translational research that was published in Science Translational Medicine, Nature Reviews Cancer, European Urology, and Cell. In recognition for my academic achievement as a PhD student I was given the Governor General’s Gold Medal. Importantly, during my time as a graduate student I was in the inaugural class of the Translational Medicine Program at the University of Alberta. This two-year program, the first of its kind in Canada, prepares clinician scientists for a career track in precision medicine and translational research.

Relevant Publications

 Kinnaird A, Brisbane W, Kwan L, Priester A, Chuang R, Barsa D, Delfin M, Sisk A, Margolis D, Felker E, Hu J, Marks LS. A prostate cancer risk calculator (PCRC-MRI): Use of Clinical+MRI data to predict biopsy outcome. (2020) Under review at Journal of Urology

Kinnaird A, Sharma V, Chuang R, Priester A, Tran E, Barsa D, Delfin M, Kwan L, Sisk A, Felker E, Marks LS. Risk of prostate cancer after a negative MRI-guided biopsy (2020) In Revision at Journal of Urology

Chuang R*, Kinnaird A*, Kwan L, Sisk A, Barsa D, Felker E, Delfin M, Marks LS. Hemi-gland cryoablation of clinically significant prostate cancer: intermediate-term follow-up via MRI-guided biopsy. (2020) IN PRESS at Journal of Urology *Co-first authors 

Kinnaird A, Boukouris A, Saleme B, Dromparis P, Zervopoulos SD, Gurtu V, Sutendra G, Michelakis D. VHL attenuates p53-dependent gene expression. (2020) In revision at Journal of Molecular Medicine

 Norris J, Kinnaird A, Margolis D, Padhani A, Walz J, Kasivisvanathan V. Developments in MRI-targeted prostate biopsy. (2020) Current Opinion in Urology 30(1): 1-8

 Kinnaird A, Zemp L, Rasmussen A, Senthilselvan, A, Chetner M, Rourke K, Schuler T. Balancing patient care with resident well-being: Analysis of changes to Urology resident inpatient workload in a universal healthcare system over a decade. (2019) Urology Practice IN PRESS

Priester A, Kinnaird A, Zhou S, Jayadevan R, Rappaport M, Delfin M, Felker E, Marks L. Focal Therapy of Prostate Cancer: Use of Tracked Biopsy Sites to Determine Treatment Margins (2019) Submitted to Journal of Urology 

Ballon J, Kinnaird A, Jayadevan R, Zhou S, Barsa D, Kwan L, Marks L. MRI-guided Biopsy to Evaluate Prostate Cancer Severity in African-American Men. (2019) Urology Practice IN PRESS

 Guorgui J, Kinnaird A, Jayadevan R, Priester A, Arnold C, Marks L. An electronic form for reporting results from targeted prostate biopsy: Urology Integrated Diagnostic Report (Uro-IDR). (2020) Urology IN PRESS 

Bain A, Kinnaird A, McLarty R, Senthilselvan A, Todd G, Chetner M. Oncological outcomes of salvage cryotherapy after primary radiation therapy versus primary cryotherapy: 10-year experience at a large Canadian referral center. (2019) CUAJ IN PRESS

 Kinnaird A and Michelakis ED. The time has come to pull renal cancer’s sweet tooth. (2019) Transl Cancer Res 8(Suppl 2):S156-S161

Saleme B, Gurtu V, Kinnaird A, Boukouris A, Wagg C, Lopaschuk G, Sutendra G. Differential regulation of p53 transcriptional activity and apoptosis by Pyruvate Kinase M2 can be therapeutically targeted in chemotherapy-induced cardiotoxicity. (2019) Science Translational Medicine 11(478)

Kinnaird A, Dromparis P, Evans H. Recurrence and upstaging rates of T1 high grade urothelial carcinoma of the bladder on repeat resection in a Canadian, resource limited, healthcare system. (2018) CUAJ 12(8):267-269

Chapman D, Cotter K, Johnsen N, Patel S, Kinnaird A, Erickson B, Voelzke B, Buckley J, Rourke K. Non-transecting techniques reduce sexual dysfunction after anastomotic bulbar urethroplasty: Results of a multi-institutional comparative analysis. (2018) Journal of Urology 201(2):364-370

 Michelakis ED, Gurtu V, Webster L, Barnes G, Watson G, Howard L, Cupitt J, Paterson I, Thompson R, Chow K, O’Regan D, Zhao L, Wharton J, Kiely D, Kinnaird A, Boukouris AE, White C, Nagendran J, Freed D, Gibbs S, Wilkins MR. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. (2017) Science Translational Medicine 9(413)

 Chapman D, Kinnaird A, Rourke KF. Independent Predictors of Stricture Recurrence Following Urethroplasty for Isolated Bulbar Urethral Strictures. (2017) Journal of Urology 198(5):1107-1112

 Kinnaird A, Zhao S, Wellen KE, Michelakis ED. Metabolic Control of Epigenetics in Cancer. (2016) Nature Reviews Cancer 16(11):694-707

 Kinnaird A, Dromparis P, Saleme B, Gurtu V, Watson K, Paulin R, Zervopoulos S, Stenson T, Sutendra G, Pink DB, Carmine-Simmen K, Moore R, Lewis JD and Michelakis ED. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase. (2016) European Urology 69(4):734-44

Rourke KF, Kinnaird A, Zorn J. Observations and outcomes of urethroplasty for bulbomembranous stenosis after radiation therapy for prostate cancer. (2016) World Journal of Urology 34(3):377-82

Forbes E, Cheung D, Kinnaird A, and St. Martin B. Zero Ischemia Robotic-Assisted Partial Nephrectomy in Alberta: Initial Results of a Novel Approach. (2015) Canadian Urological Association Journal 9(3-4):128-32

 Kinnaird A, and Michelakis ED. Metabolic Modulation of Cancer: A new frontier with great translational potential. (2015) Journal of Molecular Medicine 93(2):127-42.

Sutendra G, Kinnaird A, Dromparis P, Paulin R, Stenson TH, Haromy A, Hashimoto K, Zhang N, Flaim E and Michelakis ED. A functional nuclear pyruvate dehydrogenase complex is important for a mitochondria-independent generation of acetyl-CoA and histone acetylation. (2014) Cell 158(1):84-97

Levine M, Kinnaird A, and Rourke K. Revision urethroplasty successes is comparable to primary urethroplasty: A comparative analysis. (2014) Urology 84(4):928-32

Kinnaird A, Levine M, Ambati D, Zorn J, and Rourke K. Stricture length and etiology as preoperative independent predictors of recurrence after urethroplasty: A multivariate analysis of 604 urethroplasties. (2014) Canadian Urological Association Journal 8(5-6), e296-300

Sutendra G, Dromparis P, Kinnaird A, Stenson TH, Haromy A, Parker JM, McMurtry MS, Michelakis ED. Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer (2013). Oncogene; 32(13):1638-50

 Hoy NY, Kinnaird A, Rourke KF. Expanded use of a dorsal onlay augmented anastamotic urethroplasty with buccal mucosa for long segment bulbar urethral strictures: analysis of outcomes and complications. (2013) Urology 81(6):1357-61

Manolescu AR, Witkowska K, Kinnaird A, Cessford T, Cheeseman C. (2007) Facilitated hexose transporters: new perspectives on form and function. Physiology 22:234-40


Surgery / Oncology